Akebia Therapeutics (AKBA) Total Debt (2018 - 2026)

Akebia Therapeutics (AKBA) has 9 years of Total Debt data on file, last reported at $48.9 million in Q1 2026.

• Total Debt for Q1 2026 came in at $48.9 million, up 5.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $48.9 million (up 5.11% YoY), and the FY2025 annual result was $48.2 million, up 24.7% from the prior year.
• Total Debt improved to $48.9 million in Q1 2026 per AKBA's latest filing, from $48.2 million in the prior quarter.
• Over five years, Total Debt peaked at $98.2 million in Q2 2022 and troughed at $30.1 million in Q1 2024.
• A 5-year average of $51.9 million and a median of $47.1 million in 2025 frame the typical range for Total Debt.
• The sharpest annual moves came in 2023 and 2025: Total Debt slumped 56.72% in 2023, then soared 54.29% in 2025.
• A 5-year view of Total Debt shows it stood at $66.1 million in 2022, then slumped by 47.51% to $34.7 million in 2023, then advanced by 11.56% to $38.7 million in 2024, then increased by 24.7% to $48.2 million in 2025, then advanced by 1.33% to $48.9 million in 2026.
• Business Quant data shows AKBA's Total Debt at $48.9 million in Q1 2026, $48.2 million in Q4 2025, and $47.6 million in Q3 2025.